Cancer plasticity allows tumor cells to change their identity, evade therapies, and adapt to environmental pressures, contributing to treatment resistance and metastasis. New research is targeting this adaptability through epigenetic drugs, immune checkpoint inhibitors, and strategies to limit phenotypic switching.